

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

APPOINTMENT AND REDESIGNATION OF JONIT CHIEF EXECUTIVE OFFICER

The board of directors (the “**Board**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) hereby announces that Mr. Qin Wenhua has been appointed as the Joint Chief Executive Officer of the Company and Ms. Sun Li has been re-designated as the Joint Chief Executive Officer of the Company from the Chief Executive Officer of the Company with effect from 6 September 2022.

MR. QIN WENHUA

Mr. Qin Wenhua (“**Mr. Qin**”), aged 56, graduated from Sun Yat-sen University in 1988 with a bachelor’s degree in theoretical physics.

Mr. Qin has 28 years of experience in business start-up. He has successively led and founded various fast-moving consumer goods companies such as Yunnan Red, Yunnan Shangri-La Wine Industry, and Impression Wine Industry, all of which have developed into well-known brands in the industry. Mr. Qin has strategic framework capabilities in product design and positioning, brand marketing, consumer demand mining and service construction. He has successively established Jiangsu Weidi Electronic Trading Center Co., Ltd. (江蘇微帝電子交易中心有限公司), Shanghai Yunyang Biotechnology Co., Ltd. (上海勻養生物科技有限公司), Shanghai Meika Coffee Co., Ltd. (上海美咖咖啡有限公司), Wisdom Cloud Drink Co., Ltd. (智慧雲飲有限責任公司), Shanghai Weidi Network Technology Co., Ltd. (上海微帝網絡技術有限公司) and other companies, and has experience in the implementation of multiple consumer goods DTC projects.

The Board believes that Mr. Qin has rich experience in implementing DTC projects successfully. After being appointed as the Joint Chief Executive Officer of the Company, Mr. Qin will serve as the architect for the R&D and operation and maintenance of the Company's DTC platform, explore in-depth the brand, product and service connotation of the Company, and build the DTC platform system framework under the direct-to-consumers philosophy, so as to drive the business development of the Company.

Following the appointment of Mr. Qin as the Joint Chief Executive Officer of the Company, his service agreement with the Company has commenced on 6 September 2022 and will expire on 31 December 2022. The agreement will be renewed after submission to the Board for approval. Mr. Qin is entitled to an annual emolument of RMB470,000. The remuneration of Mr. Qin is determined by reference to his duties and responsibilities in the Company and the prevailing market conditions.

MS. SUN LI

Ms. Sun Li ("**Ms. Sun**"), aged 49, holds a doctorate degree in Business Administration from the City University of Hong Kong and graduated from Central South University with a bachelor's degree in Technological Economics and with a master's degree in Administration, respectively. Ms. Sun has engaged in investment banking for 15 years, and was among the first batch of sponsor representatives from the Securities Association of China in 2004. She is a member of Alxa SEE Conservation, an environmental protection charity organization for Chinese entrepreneurs. From May 2013 until now, she served as president, director and co-partner of Beijing Yingguxinye Investment Co., Ltd (北京盈谷信曠投資有限公司). In September 2014, she was the founding member of Tianjin Teda "Wings of the Angel" Investor Club. From May 2015 until now, she was appointed as supervisors of Shenzhen Xiangyong Investment Company Limited and Dongguan Lvye Fertilisers Company Limited. From September 2015 until now, she, as the beneficial owner of Beijing Tianyuhongtai Technology Co., Ltd. (北京天宇鴻泰科技有限公司), held its 16% shares. From December 2015 until now, she was appointed as a director of Beijing Yingguchuangrong Information Technology Co., Ltd. (北京盈谷創融信息科技股份有限公司). From August 2015 until now, Ms. Sun was appointed as an executive director and the Chairman of the Board of the Company. From September 2015 to January 2019 and from 30 December 2019, she concurrently serves Officer of the Company.

Ms. Sun has entered into a letter of appointment as an executive director with the Company for a term of three years commencing from 30 December 2019. Ms. Sun will be entitled to a remuneration of RMB530,000 per annum for her appointment as the Chairman of the Board, Executive Director and CEO of the Company. Ms. Sun's remuneration is determined with reference to her responsibilities and duties with the Company and current market condition.

As at the date of this announcement, Ms. Sun holds a long position in 300,000,000 shares of the Company, representing 15.83% of the total issued share capital. Out of these shares, 180,000,000 shares are held by Shenzhen Xiangyong Investment Company Limited (“**Xiangyong Investment**”) and 120,000,000 shares are held by Dongguan Lvye Fertilizers Company Limited (“**Lvye Fertilizers**”). Ms. Sun is the beneficial owner of Beijing Yingguxinye Investment Co., Ltd. (“**Yingguxinye**”) holding its 15% equity interest, while Yingguxinye holds 100% equity interest in Xiangyong Investment and Lvye Fertilizers respectively. In addition, neither Ms. Sun nor Mr. Qin has any other interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, Ms. Sun serves as the chairman of the Board, an executive director, the chairman of the nomination committee, a member of the remuneration committee of the Company and a director and general manager of several subsidiaries of the Group. Mr. Qin serves as a director and general manager of Shanghai Weidi Network Technology Co., Ltd. (上海微帝網路技術有限公司), a subsidiary of the Company. Save as disclosed above, as at the date of this announcement, Ms. Sun and Mr. Qin (i) did not hold any other positions in the Company or other members of the Company; (ii) did not have any other relationships with any Directors, senior management, substantial or controlling shareholders of the Company; and (iii) did not hold any directorship, and other major appointments and qualifications in public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years.

Ms. Sun and Mr. Qin have confirmed that, save as disclosed above, there is no information in relation to appointment and re-designation of the Joint Chief Executive Officer which is discloseable pursuant to Rules 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of the Stock Exchange, or any other matters that need to be brought to the attention of the Shareholders.

The Board wishes to congratulate Mr. Qin on his appointment as the Joint Chief Executive Officer of the Company and Ms. Sun on her re-designation as the Joint Chief Executive Officer.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
6 September 2022

As at the date of this announcement, the executive directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.